# A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors

> **NCT01778439** · PHASE1 · COMPLETED · sponsor: **OncoMed Pharmaceuticals, Inc.** · enrollment: 48 (actual)

## Conditions studied

- Relapsed or Refractory Solid Tumors

## Interventions

- **DRUG:** OMP-52M51

## Key facts

- **NCT ID:** NCT01778439
- **Lead sponsor:** OncoMed Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2020-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01778439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01778439, "A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT01778439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*